<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The global epidemic of <z:hpo ids='HP_0001513'>obesity</z:hpo> is accompanied by an increased prevalence of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>), in particular <z:hpo ids='HP_0001297'>stroke</z:hpo> and <z:e sem="disease" ids="C0027051" disease_type="Disease or Syndrome" abbrv="MR|mi|AMI">heart attack</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Dysfunctional adipose tissue links <z:hpo ids='HP_0001513'>obesity</z:hpo> to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> by secreting a multitude of bioactive <z:chebi fb="23" ids="18059">lipids</z:chebi> and pro-inflammatory factors (adipokines) with detrimental effects on the cardiovascular system </plain></SENT>
<SENT sid="2" pm="."><plain>Adiponectin is one of the few adipokines that possesses multiple salutary effects on insulin sensitivity and cardiovascular health </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical investigations have identified adiponectin deficiency (hypoadiponectinaemia) as an independent risk factor for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In animals, elevation of plasma adiponectin by either pharmacological or genetic approaches alleviates <z:hpo ids='HP_0001513'>obesity</z:hpo>-induced <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> and <z:hpo ids='HP_0000822'>hypertension</z:hpo>, and also prevents <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo>, <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> and diabetic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, many therapeutic benefits of the peroxisome-proliferator activated receptor gamma <z:chebi fb="4" ids="48705">agonists</z:chebi>, the <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi>, are mediated by induction of adiponectin </plain></SENT>
<SENT sid="6" pm="."><plain>Adiponectin protects cardiovascular health through its <z:chebi fb="1" ids="35620">vasodilator</z:chebi>, anti-apoptotic, anti-inflammatory and anti-oxidative activities in both cardiac and vascular cells </plain></SENT>
<SENT sid="7" pm="."><plain>This review summarizes recent findings in the understanding of the physiological role and clinical relevance of adiponectin in cardiovascular health, and in the identification of the receptor and postreceptor signalling events that mediate the cardiovascular actions of adiponectin </plain></SENT>
<SENT sid="8" pm="."><plain>It also discusses adiponectin-targeted drug discovery strategies for treating <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>LINKED ARTICLES: This article is part of a themed section on Fat and Vascular Responsiveness </plain></SENT>
<SENT sid="10" pm="."><plain>To view the other articles in this section visit http://dx.doi.org/10.1111/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">bph</z:e>.2012.165.issue-3 </plain></SENT>
</text></document>